Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Shana Tova 5781 https://t.co/2i3E8WZN1y #Science #Business
    about 1 day ago
  • When even PhRMA doesn't want to be a Trump campaign prop ... A Deal on Drug Prices Undone by White House Insistence… https://t.co/JjdVxOTVV6
    about 2 days ago
  • A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $… https://t.co/D8kwt0ng5X
    about 2 days ago
  • New post on Science and Enterprise: Mental Health Drug Company Raises $127.5M in IPO https://t.co/39Xea7VQpV #Science #Business
    about 2 days ago
  • A test for SARS-CoV-2 viruses is shown in field tests to return diagnostic results in 90 minutes with accuracy comp… https://t.co/EuQIPTsL57
    about 2 days ago

Please share Science & Enterprise

Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy

lung illustration

Two biotechnology companies are adding to their current collaboration to develop delivery techniques for gene-editing treatments for cystic fibrosis. . . . → Read More: Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy

Early Trial Results Show Antibody Treating Covid-19

SARS-Cov-2 virus

First results from a clinical trial testing an experimental synthetic antibody, show patients receiving the therapy at a specific dosage, cleared their SARS-CoV-2 viruses within 11 days. . . . → Read More: Early Trial Results Show Antibody Treating Covid-19

Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Human T-cell

A company creating cancer therapies with individualized engineered T-cells is raising $110 million in its first venture funding round. . . . → Read More: Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Gilead Acquires Cancer Therapy Biotech for $21B

Investment graphic

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Antibody Discovery Company Forms, Partners on Covid-19

Network pointer

A new enterprise formed to discover human therapeutic antibodies is partnering with a synthetic biology company to discover Covid-19 antibody treatments. . . . → Read More: Antibody Discovery Company Forms, Partners on Covid-19

Biotechs, Pharmas Vow Not to Rush Covid-19 Vaccines

Syrine ingloved hand

In a joint statement today, CEOs of nine companies promised to follow the highest ethical and scientific standards in development and testing of their Covid-19 vaccines. . . . → Read More: Biotechs, Pharmas Vow Not to Rush Covid-19 Vaccines

Sanofi, GSK Begin U.S. Covid-19 Vaccine Trial

Syringes

Global drug makers Sanofi and GlaxoSmithKline are starting a clinical trial testing a vaccine to prevent Covid-19 infections among healthy adults in the U.S. . . . → Read More: Sanofi, GSK Begin U.S. Covid-19 Vaccine Trial

Synthetic Antibodies Neutralize Covid-19 Virus Proteins

SARS-Cov-2 virus

A company developing synthetic genetic materials and proteins says independent tests show its artificial antibodies neutralize infection mechanisms in Covid-19 viruses. . . . → Read More: Synthetic Antibodies Neutralize Covid-19 Virus Proteins

Late-Stage Covid-19 Vaccine Trial Underway in U.S.

Covid-19 vaccine infographic

Global drug maker AstraZeneca is starting its late-stage Covid-19 vaccine clinical trial in the U.S., with a vow not to cut corners in its processes. . . . → Read More: Late-Stage Covid-19 Vaccine Trial Underway in U.S.

Food Allergy Biotech Acquired for $2.6B

Palforzia capsules

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B